HC Wainwright Cuts Earnings Estimates for Coya Therapeutics

Coya Therapeutics, Inc. (NASDAQ:COYA) – Analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Coya Therapeutics in a research note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.39) for the quarter, down from their prior forecast of ($0.33). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.64) EPS.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The business had revenue of $3.96 million for the quarter, compared to analyst estimates of $1.93 million.

Several other equities analysts have also recently commented on COYA. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Coya Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Stock Up 1.2%

Shares of COYA opened at $4.20 on Wednesday. Coya Therapeutics has a fifty-two week low of $3.94 and a fifty-two week high of $7.75. The firm’s 50 day moving average price is $4.66 and its 200 day moving average price is $5.47. The company has a market cap of $98.52 million, a P/E ratio of -3.31 and a beta of 0.23.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in Coya Therapeutics during the fourth quarter worth approximately $192,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Coya Therapeutics in the fourth quarter valued at approximately $66,000. Millennium Management LLC purchased a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $121,000. 683 Capital Management LLC acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $465,000. Finally, Cetera Investment Advisers purchased a new stake in Coya Therapeutics in the 4th quarter valued at $128,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Key Stories Impacting Coya Therapeutics

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained an $18 price target on COYA, a signal of analyst conviction that can support investor demand. HC Wainwright Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)
• Positive Sentiment: HC Wainwright nudged its Q4 2026 estimate slightly higher (from ($0.46) to ($0.43) EPS), a modest improvement for late-2026 profitability expectations that could be viewed positively by investors.
• Neutral Sentiment: HC Wainwright published multi-year forecasts (Q1–Q4 2027 and FY2027 EPS of around ($1.66)); these longer-horizon projections provide context but are farther out and less likely to move the stock near term.
• Neutral Sentiment: Public short-interest postings in March show “0 shares” and NaN changes — an apparent data/reporting anomaly. That reduces the usefulness of the short-interest signal for explaining price moves today.
• Negative Sentiment: HC Wainwright cut several near-term 2026 EPS forecasts: Q1 (to ($0.39) from ($0.33)), Q2 (to ($0.39) from ($0.33)), Q3 (to ($0.41) from ($0.40)) and lowered FY2026 to ($1.64) from ($1.52). These downgrades reflect weaker near-term profitability expectations and likely weigh on sentiment.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.